Fri May 09 02:30:00 UTC 2025: **Nasal Vaccines Show Promise Against Respiratory Infections: A Review**
**London, UK** – A new review published in *Nature* highlights the potential of nasal vaccines to combat respiratory infections, offering a significant advance over existing injectable vaccines. While injectable vaccines, such as the revolutionary mRNA COVID-19 vaccines, have proven effective in reducing disease severity, they have limitations in preventing viral invasion at respiratory surfaces and transmission.
The review, authored by Hiroshi Kiyono and Peter B. Ernst, examines the development of nasal vaccines, which aim to induce both serum IgG and secretory IgA antibodies. Secretory IgA antibodies are crucial for preventing pathogen invasion at mucosal surfaces, thus potentially reducing both disease severity and transmission.
The authors discuss the complex anatomical, physiological, and immunological factors that must be considered in nasal vaccine design, including the proximity of the nasal cavity to the central nervous system. They review past and current research efforts, highlighting innovative delivery systems and different vaccine platforms explored, such as viral vectors (adenoviruses, parainfluenza virus), bacterial vectors (Lactobacillus), and nanogel-based systems. The review also delves into various delivery mechanisms and the importance of mucosal immune responses.
While acknowledging challenges, the review concludes that nasal vaccines represent a promising strategy for preventing respiratory infections and preparing for future pandemics. The potential for broader protection and ease of administration makes nasal vaccines an important area of ongoing research. Further research and development are needed to ensure the safety and efficacy of these vaccines before widespread implementation.
First Piper 